Colorectal carcinoma (CRC) · line 2 · Trastuzumab-deruxtecan monotherapy (DESTINY-CRC01, HER2+ mCRC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-TRASTUZUMAB-DERUXTECAN-CRC |
| ID | IND-CRC-METASTATIC-2L-HER2-AMP-T-DXD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-CRC |
| Sources | SRC-DESTINY-CRC01-SIENA-2021 SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ alternative for HER2-amp RAS-WT mCRC. ESCAT IIA. Trial-specific source (DESTINY-CRC01 PMID 34637687) not in KB yet — flagged for CSD-4.5. Position vs tucatinib-trastuzumab covered in known_controversies. ILD surveillance protocol is the key implementation detail.
Used By
Algorithms
ALGO-CRC-METASTATIC-2L- ALGO-CRC-METASTATIC-2L